litlas
Log inCreate account

Stuart C. Gordon

Active 1984–2025

113
Papers
35,272
Citations
79
h-index
108
i10-index

Citations

Citations per year for Stuart C. Gordon1985: 1 citations1986: 2 citations1987: 1 citations1988: 2 citations1989: 2 citations1990: 1 citations1991: 2 citations1992: 4 citations1993: 3 citations1994: 4 citations1995: 5 citations1996: 4 citations1997: 13 citations1998: 13 citations1999: 56 citations2000: 118 citations2001: 118 citations2002: 215 citations2003: 178 citations2004: 189 citations2005: 214 citations2006: 197 citations2007: 194 citations2008: 161 citations2009: 151 citations2010: 199 citations2011: 201 citations2012: 206 citations2013: 220 citations2014: 318 citations2015: 374 citations2016: 349 citations2017: 268 citations2018: 252 citations2019: 768 citations2020: 639 citations2021: 504 citations2022: 388 citations2023: 296 citations2024: 490 citations2025: 213 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,667 citing papers, 28.4% of this breakdownUnited Kingdom: 579 citing papers, 6.1% of this breakdownFrance: 570 citing papers, 6.1% of this breakdownGermany: 564 citing papers, 6% of this breakdownItaly: 562 citing papers, 6% of this breakdownChina: 542 citing papers, 5.8% of this breakdownCanada: 337 citing papers, 3.6% of this breakdownJapan: 328 citing papers, 3.5% of this breakdownSpain: 304 citing papers, 3.2% of this breakdownAustralia: 262 citing papers, 2.8% of this breakdownBelgium: 189 citing papers, 2% of this breakdownNetherlands: 183 citing papers, 1.9% of this breakdown
0%28.4%Other 24.6%

Institutions

Fields

  • Medicine90.2%
  • Biochemistry, Genetics and Molecular Biology3.4%
  • Immunology and Microbiology2.6%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Neuroscience0.4%
  • Chemistry0.4%
  • Other2.1%

Topics

  • Hepatitis C virus research17.7%
  • Liver Disease Diagnosis and Treatment15.1%
  • Hepatitis B Virus Studies9.3%
  • Liver Diseases and Immunity3.9%
  • Liver Disease and Transplantation3.7%
  • HIV/AIDS drug development and treatment3.6%
  • Other46.7%

Coauthors

All papers

Open in search
  1. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Authors: Vlad Ratziu, Stephen A. Harrison, Sven Francque, Pierre Bédossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero‐Gómez, Jérôme Boursier, Manal F. Abdelmalek, Steve Caldwell, Joost P.H. Drenth, Quentin M. Anstee, Dean W. Hum, Rémy Hanf, A. Roudot, S. Megnien, Bart Staels, Arun J. Sanyal, Philippe Mathurin, Jérôme Gournay, Éric Nguyen-Khac, Victor de Lédinghen, Dominique Larrey, Albert Tran, Marc Bourlière, M. Maynard-Muet, Tarik Asselah, Jean Henrion, Frederik Nevens, David Cassiman, Anja Geerts, Christophe Moreno, Ulrich Beuers, Peter R. Galle, U. Spengler, Elisabetta Bugianesi, Antonio Craxı̀, M. Angélico, Silvia Fargion, M Voiculescu, Liliana Gheorghe, Liliana Preoțescu, Juan Caballería, Raúl J. Andrade, Javier Crespo, J.L. Callera, Aftab Ala, Guruprasad P. Aithal, George Abouda, Velimir A. Luketic, Mao-Yu Huang, Stuart C. Gordon, Paul J. Pockros, Fred Poordad, Nathan J. Shores, Martin Moehlen, Kiran Bambha, Virginia Clark, Sanjaya K. Satapathy, Samir Parekh, R.K. Reddy, Muhammad Y. Sheikh, Gyöngyi Szabó, John M. Vierling, Timothy E. Foster, Guillermo E. Umpierrez, Chih‐Jen Chang, Terry Box, Juan F. Gallegos‐Orozco - Gastroenterology 2016 cited by 1,014

  2. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

    Authors: Zobair M. Younossi, Saleh A. Alqahtani, Khalid Alswat, Yusuf Yılmaz, Çağlayan Keklikkıran, Jesús Funuyet‐Salas, Manuel Romero‐Gómez, Jian‐Gao Fan, Ming‐Hua Zheng, Mohamed El‐Kassas, Laurent Castéra, Chun‐Jen Liu, Vincent Wai‐Sun Wong, Shira Zelber‐Sagi, Alina M. Allen, Brian Lam, Sombat Treeprasertsuk, Saeed Hameed, Hirokazu Takahashi, Takumi Kawaguchi, Jörn M. Schattenberg, Ajay Duseja, Philip N. Newsome, Sven Francque, C Wendy Spearman, Marlen I. Castellanos Fernández, Patrizia Burra, Stuart K. Roberts, Wah‐Kheong Chan, Marco Arrese, Marcelo Silva, Mary E. Rinella, Ashwani K. Singal, Stuart C. Gordon, Michael Fuchs, Naim Alkhouri, Kenneth Cusi, Rohit Loomba, Jane Ranagan, Wayne Eskridge, Achim Kautz, Janus P. Ong, Marcelo Kugelmas, Yuichiro Eguchi, M. Diago, Ming‐Lung Yu, Lynn H. Gerber, Lisa Fornaresio, Fatema Nader, Linda Henry, Andrei Racila, Pegah Golabi, Maria Stepanova, Patrizia Carrieri, Jeffrey V. Lazarus - Journal of Hepatology 2023 cited by 96

  3. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

    Authors: Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Kris V. Kowdley, John M. Vierling, Cynthia Levy, Andreas E. Kremer, Ehud Zigmond, Pietro Andreoné, Stuart C. Gordon, Christopher L. Bowlus, Eric Lawitz, Richard Aspinall, Daniel S. Pratt, K. L. Raikhelson, M.S. González-Huezo, Michael A. Heneghan, Sook‐Hyang Jeong, Alma Laura Ladrón De Guevara, Marlyn J. Mayo, George Ν. Dalekos, Joost P.H. Drenth, Ewa Janczewska, Barbara Leggett, Frederik Nevens, Vı́ctor Vargas, Eli Zuckerman, Christophe Corpechot, E Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak Trivedi, Lisa Forman, David E.J. Jones, Stephen Ryder, Mark G. Swain, Alexandra Steinberg, Pol Boudes, Yun‐Jung Choi, Charles A. McWherter, ENHANCE Study Group* - Hepatology 2023 cited by 113

  4. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

    Authors: AASLD-IDSA HCV Guidance Panel, Raymond T. Chung, Marc G. Ghany, Arthur Y Kim, Kristen Marks, Susanna Naggie, Hugo E. Vargas, Andrew Aronsohn, Debika Bhattacharya, Tina Broder, Oluwaseun Falade‐Nwulia, Robert J. Fontana, Stuart C. Gordon, Theo Heller, Scott D. Holmberg, Ravi Jhaveri, Maureen M. Jonas, Jennifer J. Kiser, Benjamin P. Linas, Vincent Lo Re, Timothy R. Morgan, Ronald Nahass, Marion G. Peters, K. Rajender Reddy, Andrew Reynolds, John D. Scott, Gloria Searson, Tracy Swan, Norah A. Terrault, Stacey Trooskin, John B. Wong, Kimberly Workowski - Clinical Infectious Diseases 2018 cited by 726

  5. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

    Authors: Gideon M. Hirschfield, Andrew L. Mason, Velimir A. Luketic, Keith D. Lindor, Stuart C. Gordon, Marlyn J. Mayo, Kris V. Kowdley, Catherine Vincent, Henry C. Bodhenheimer, Albert Parés, Michael Trauner, Hanns–Ulrich Marschall, Luciano Adorini, Cathi Sciacca, T. Beecher-Jones, Erin Castelloe, O. Böhm, Д. А. Шапиро - Gastroenterology 2014 cited by 565

  6. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry

    Authors: Zobair M. Younossi, Yusuf Yılmaz, Ming‐Lung Yu, Vincent Wai‐Sun Wong, Marlen Castellanos Fernández, Isakov Va, Ajay Duseja, Nahúm Méndez‐Sánchez, Yuichiro Eguchi, Elisabetta Bugianesi, Patrizia Burra, Jacob George, Jian‐Gao Fan, George Papatheodoridis, Wah‐Kheong Chan, Khalid Alswat, Hamid S. Saeed, Ashwani K. Singal, Manuel Romero‐Gómez, Stuart C. Gordon, Stuart K. Roberts, Mohamed El‐Kassas, Marcelo Kugelmas, Janus P. Ong, Saleh A. Alqahtani, Mariam Ziayee, Brian Lam, Issah Younossi, Andrei Racila, Linda Henry, Maria Stepanova - Clinical Gastroenterology and Hepatology 2021 cited by 106

  7. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

    Authors: David Jones, Pol Boudes, Mark G. Swain, Christopher L. Bowlus, Michael Galambos, Bruce R. Bacon, Yvonne Döerffel, Norman Gitlin, Stuart C. Gordon, Joseph A. Odin, David Sheridan, M A Wörns, Virginia Clark, Linsey Corless, Heinz Hartmann, Mark Jonas, Andreas E. Kremer, George Mells, Peter Buggisch, B. Freilich, Cynthia Levy, John M. Vierling, David Bernstein, Marek Hartleb, Ewa Janczewska, Fedja A. Rochling, Hemant Shah, Mitchell L. Shiffman, John H. Smith, Yun‐Jung Choi, Alexandra Steinberg, Mónika Varga, Harinder Chera, Robert L. Martin, Charles A. McWherter, Gideon M. Hirschfield - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 186

  8. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

    Authors: Rohit Loomba, Robert J. Wong, Jeremy Fraysse, Sanatan Shreay, Suying Li, Stephen A. Harrison, Stuart C. Gordon - Alimentary Pharmacology & Therapeutics 2020 cited by 180

  9. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

    Authors: Christopher L. Bowlus, Michael Galambos, Richard Aspinall, Gideon M. Hirschfield, David E.J. Jones, Yvonne Dörffel, Stuart C. Gordon, Stephen A. Harrison, Andreas E. Kremer, Marlyn J. Mayo, Paul J. Thuluvath, Cynthia Levy, Mark G. Swain, Guy Neff, David Sheridan, Carmen Stanca, Christoph P. Berg, Aparna Goel, Mitchell L. Shiffman, John M. Vierling, Pol Boudes, Alexandra Steinberg, Yun‐Jung Choi, Charles A. McWherter - Journal of Hepatology 2022 cited by 79

  10. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

    Authors: W. Ray Kim, Thomas Berg, Tarik Asselah, Robert Flisiak, Scott Fung, Stuart C. Gordon, Harry L.A. Janssen, Pietro Lampertico, Daryl Lau, Jeffrey D. Bornstein, Raul E. Aguilar Schall, Phillip Dinh, Leland J. Yee, Eduardo B. Martins, Seng Gee Lim, Rohit Loomba, Jörg Petersen, Marı́a Buti, Patrick Marcellin - Journal of Hepatology 2015 cited by 291

  11. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

    Authors: Marc Bourlière, Stuart C. Gordon, Steven L. Flamm, Curtis Cooper, Alnoor Ramji, Myron J. Tong, Natarajan Ravendhran, Simon C. Ling, Tram T. Tran, Stephen Pianko, Meena B. Bansal, Victor de Lédinghen, Robert H. Hyland, Luisa M. Stamm, Hadas Dvory‐Sobol, Evguenia S. Svarovskaia, Jie Zhang, Kaijiao Huang, G. Mani Subramanian, Diana M. Brainard, John G. McHutchison, Elizabeth C. Verna, Peter Buggisch, Charles Landis, Ziad Younes, Michael P. Curry, Simone I. Strasser, Eugene R. Schiff, K. Rajender Reddy, M.P. Manns, Kris V. Kowdley, Stefan Zeuzem - New England Journal of Medicine 2017 cited by 565

  12. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment

    Authors: Mei Lü, Yueren Zhou, Irina V. Haller, Robert J. Romanelli, Jeffrey J. VanWormer, Carla V. Rodriguez, Heather Anderson, Joseph A. Boscarino, Mark A. Schmidt, Yihe G. Daida, Amandeep Sahota, Jennifer Vincent, Christopher L. Bowlus, Keith D. Lindor, Talan Zhang, Sheri Trudeau, Jia Li, Loralee B. Rupp, Stuart C. Gordon - Clinical Gastroenterology and Hepatology 2017 cited by 135

  13. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

    Authors: Anna S. Lok, Calvin Q. Pan, Steven-Huy Han, Huy N. Trinh, W. Jeffrey Fessel, Timothy C. Rodell, Benedetta Massetto, Lanjia Lin, Anuj Gaggar, G. Mani Subramanian, John G. McHutchison, Carlo Ferrari, Hannah Lee, Stuart C. Gordon, Edward Gane - Journal of Hepatology 2016 cited by 177

  14. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

    Authors: Marlyn J. Mayo, John M. Vierling, Christopher L. Bowlus, Cynthia Levy, Gideon M. Hirschfield, Guy Neff, Michael Galambos, Stuart C. Gordon, Brian B. Borg, Stephen A. Harrison, Paul J. Thuluvath, Aparna Goel, Mitchell L. Shiffman, Mark G. Swain, David Jones, Palak Trivedi, Andreas E. Kremer, Richard Aspinall, David Sheridan, Yvonne Dörffel, Ke Yang, Yun‐Jung Choi, Charles A. McWherter - Alimentary Pharmacology & Therapeutics 2023 cited by 35

  15. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Authors: Graham R. Foster, Nezam H. Afdhal, Stuart K. Roberts, Norbert Bräu, Edward Gane, Stephen Pianko, Eric Lawitz, Alexander Thompson, Mitchell L. Shiffman, Curtis Cooper, William Towner, Brian Conway, Peter Ruane, Marc Bourlière, Tarik Asselah, Thomas Berg, Stefan Zeuzem, William Rosenberg, Kosh Agarwal, Catherine Stedman, Hongmei Mo, Hadas Dvory‐Sobol, Lingling Han, Jing Wang, John McNally, Anu Osinusi, Diana M. Brainard, John G. McHutchison, Francesco Mazzotta, Tram T. Tran, Stuart C. Gordon, Keyur Patel, Nancy Reau, Alessandra Mangia, Mark Sulkowski - New England Journal of Medicine 2015 cited by 850

  16. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

    Authors: Zobair M. Younossi, Saleh A. Alqahtani, Jesús Funuyet‐Salas, Manuel Romero‐Gómez, Yusuf Yılmaz, Çağlayan Keklikkıran, Khalid Alswat, Ming‐Lung Yu, Chun‐Jen Liu, Jian‐Gao Fan, Ming‐Hua Zheng, Patrizia Burra, Sven Francque, Laurent Castéra, Jörn M. Schattenberg, Philip N. Newsome, Alina M. Allen, Mohamed El‐Kassas, Sombat Treeprasertsuk, Saeed Hameed, Vincent Wai‐Sun Wong, Shira Zelber‐Sagi, Kazuhiro Takahashi, Takumi Kawaguchi, Marlen I. Castellanos Fernández, Ajay Duseja, Marco Arrese, Mary E. Rinella, Ashwani K. Singal, Stuart C. Gordon, Michael Fuchs, Wayne Eskridge, Naim Alkhouri, Kenneth Cusi, Rohit Loomba, Jane Ranagan, Achim Kautz, Janus P. Ong, Marcelo Kugelmas, Yuichiro Eguchi, M. Diago, Lynn H. Gerber, Brian Lam, Lisa Fornaresio, Fatema Nader, C Wendy Spearman, Stuart K. Roberts, Wah‐Kheong Chan, Marcelo Silva, Andrei Racila, Pegah Golabi, Prooksa Ananchuensook, Linda Henry, Maria Stepanova, Patrizia Carrieri, Jeffrey V. Lazarus - JHEP Reports 2024 cited by 31

  17. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

    Authors: Eric Lawitz, Alessandra Mangia, David Wyles, M. Rodríguez‐Torres, Tarek Hassanein, Stuart C. Gordon, Michael Schultz, Mitchell Davis, Zeid Kayali, K. Rajender Reddy, Ira M. Jacobson, Kris V. Kowdley, Lisa M. Nyberg, G. Mani Subramanian, Robert H. Hyland, Sarah Arterburn, Deyuan Jiang, John McNally, Diana M. Brainard, William T. Symonds, John G. McHutchison, Aasim Sheikh, Zobair M. Younossi, Edward Gane - New England Journal of Medicine 2013 cited by 1,782

  18. Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices

    Authors: Zobair M. Younossi, Kathleen E. Corey, Naim Alkhouri, Mazen Noureddin, Ira M. Jacobson, Brian Lam, Stephen Clement, Rita Basu, Stuart C. Gordon, Natarajan Ravendhra, Puneet Puri, Mary E. Rinella, Peter Scudera, Ashwani K. Singal, Linda Henry - Alimentary Pharmacology & Therapeutics 2020 cited by 93

  19. Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems

    Authors: Mei Lü, Jia Li, Irina V. Haller, Robert J. Romanelli, Jeffrey J. VanWormer, Carla V. Rodriguez, Marsha A. Raebel, Joseph A. Boscarino, Mark A. Schmidt, Yihe G. Daida, Amandeep Sahota, Jennifer Vincent, Christopher L. Bowlus, Keith D. Lindor, Loralee B. Rupp, Stuart C. Gordon, Rene Everline, Zahra Daar, Christina Melkonian, Talan Zhang, Yueren Zhou, Hank Wu, Dana Larkin, Nishat Islam, Nonna Akkerman, Sheri Trudeau, Diane Kohnhorst, Sally F. Shaw, Vicki Y. Chiu, Judy Donald, M.F. Turner, Kevin Rubenstein, Jacquelyn Redd, Carmen Wong, Joanne Mor, Kathy Bow, Lisa E. Pieper, Heather Anderson, Nathan Tesch, Solomon Trimble, Mario J. De Los Santos, Tina Amlin, Shamyal Khan, Kevin Dunlap - Clinical Gastroenterology and Hepatology 2017 cited by 79

  20. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases

    Authors: Robert J. Wong, Nandita Kachru, Diane Martinez, Meghan Moynihan, A. Burak Ozbay, Stuart C. Gordon - Journal of Clinical Gastroenterology 2020 cited by 48

  21. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

    Authors: Andrew J. Muir, Sanjeev Arora, Gregory T. Everson, Robert Flisiak, Jacob George, Reem Ghalib, Stuart C. Gordon, Todd Gray, Susan Greenbloom, Tarek Hassanein, Jan Hillson, Maria Arantxa Horga, Ira M. Jacobson, Lennox Jeffers, Kris V. Kowdley, Eric Lawitz, Stefan Lueth, M. Rodríguez‐Torres, Vinod K. Rustgi, Lynn Shemanski, Mitchell L. Shiffman, Subasree Srinivasan, Hugo E. Vargas, John M. Vierling, Dong Xu, Juan Carlos López-Talavera, Stefan Zeuzem - Journal of Hepatology 2014 cited by 147

  22. Advancing Age and Comorbidity in a US Insured Population‐Based Cohort of Patients With Chronic Hepatitis B

    Authors: Mindie H. Nguyen, Joseph K. Lim, A. Burak Ozbay, Jeremy Fraysse, Iris Liou, Nicole Meyer, Geoffrey Dusheiko, Stuart C. Gordon - Hepatology 2018 cited by 87

  23. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

    Authors: Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy, Lorenzo Rossaro, David Bernstein, Eric Lawitz, Mitchell L. Shiffman, Eugene R. Schiff, Reem Ghalib, Michael J. Ryan, Vinod K. Rustgi, Mario Chojkier, Robert Herring, Adrian M. Di Bisceglie, Paul J. Pockros, G. Mani Subramanian, Di An, Evguenia S. Svarovskaia, Robert H. Hyland, Phillip S. Pang, William T. Symonds, John G. McHutchison, Andrew J. Muir, David Pound, Michael Fried - New England Journal of Medicine 2014 cited by 1,125

  24. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

    Authors: Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley, Eric M. Yoshida, M. Rodríguez‐Torres, Mark Sulkowski, Mitchell L. Shiffman, Eric Lawitz, Gregory T. Everson, Michael Bennett, Eugene R. Schiff, M. Tarek Al-Assi, G. Mani Subramanian, Di An, M. Lin, John McNally, Diana M. Brainard, William T. Symonds, John G. McHutchison, Keyur Patel, Jordan J. Feld, Stephen Pianko, David R. Nelson - New England Journal of Medicine 2013 cited by 1,082